Last updated: February 27, 2026
What is NDC: 70000-0174?
The drug identified by NDC 70000-0174 is Rucaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor used primarily for the treatment of ovarian cancer. Approved by the FDA in 2018 under the brand name Rubraca, it is indicated for treatment of advanced ovarian cancer, including BRCA-mutated cancers.
Current Market Size and Demand
Market Overview
- Indications: Treatment of BRCA-mutated ovarian cancer, recurrent ovarian cancer
- Estimated US patient population (2023): 20,000–25,000 eligible patients annually
- Global demand forecasted to grow at a Compound Annual Growth Rate (CAGR) of 7% from 2023 to 2028 (Source: IQVIA)
Market Drivers
- Rising incidence of ovarian cancer
- Increasing approval for additional indications such as prostate and breast cancers
- Growing adoption of PARP inhibitors in oncology treatment protocols
- Advances in companion diagnostics for BRCA mutations
Competitive Landscape
Main competitors include:
- Lynparza (olaparib) by AstraZeneca
- Zejula (niraparib) by GSK
- Other emerging PARP inhibitors in late-stage development
Market share predominately favors Lynparza, with an estimated 60% of PARP-inhibitor sales, followed by Zejula and others.
Sales Breakdown (2022)
| Product |
Estimated Sales (USD Millions) |
Market Share (%) |
| Lynparza |
1,700 |
50 |
| Zejula |
870 |
25 |
| Rubraca |
600 |
18 |
| Others |
200 |
7 |
Price Projections: Current and Future
Current Pricing
- Wholesale Acquisition Cost (WAC) per month: $12,000 – $13,000
- Average annual treatment cost: $144,000 – $156,000
Factors Affecting Future Pricing
-
Patent Expiry and Biosimilar Entry
- Patent protection for Rubraca extends to 2034.
- No biosimilars or generics available yet; market exclusivity remains.
-
Regulatory and Reimbursement Trends
- Favorable reimbursement policies under Medicare and private insurers.
- Potential for price adjustments in response to competition and value-based agreements.
-
Market Penetration and Adoption Rates
- Expected to reach 55–60% of eligible patients by 2028.
- Increasing use in combination therapies could influence future pricing strategies.
Price Projection Outlook (2023–2028)
| Year |
Estimated Average Annual Cost (USD) |
Key Factors |
| 2023 |
$150,000 |
Market lock-in, limited biosimilar presence |
| 2024 |
$147,000 |
Price erosion anticipated due to increased competition |
| 2025 |
$144,000 |
Market stabilization, potential price negotiation impacts |
| 2026 |
$142,000 |
Introduction of biosimilar candidates in late development |
| 2027 |
$140,000 |
Biosimilar or alternative PARP inhibitors gain market share |
Market Impact of Biosimilar Entry
- Prices may decline by 20–30% upon biosimilar launch, expected by 2028–2030.
- Historical precedent with similar oncology drugs indicates rapid price reductions post-generic entry (Source: IMS Health).
Financial Outlook and Revenue Projections
Revenue Projections (2023–2028)
| Year |
Estimated Global Revenue (USD Millions) |
Assumptions |
| 2023 |
600 |
Growth driven by increased adoption in ovarian and other cancers |
| 2024 |
650 |
Market expansion, stable pricing |
| 2025 |
700 |
Reimbursement expansion across new regions |
| 2026 |
750 |
Biosimilar competition begins influencing prices |
| 2027 |
700 |
Price erosion, higher biosimilar market penetration |
Key Market Risks and Opportunities
Risks
- Patent expiration delaying maximum profitability.
- Price erosion from biosimilar competition.
- Regulatory shifts affecting pricing and reimbursement.
Opportunities
- Expanding indications (e.g., prostate, breast cancers).
- Combination therapy approvals increasing market size.
- Geographic expansion in emerging markets.
Summary Conclusion
Rucaparib (NDC 70000-0174) currently commands a premium price with annual treatment costs around $150,000. Market growth driven by rising ovarian cancer cases and expanding indications supports continued revenue expansion until biosimilar entry around 2028–2030, which could reduce prices by as much as 30%. The drug maintains a strong position but faces typical patent expiration challenges and competitive pressures.
Key Takeaways
- Rucaparib is a leading PARP inhibitor with significant market share in ovarian cancer.
- Current average treatment price is approximately $150,000 annually.
- Market growth is expected to favorably impact revenues until biosimilar competition emerges, likely between 2028 and 2030.
- Price reductions of 20–30% are anticipated with biosimilar availability.
- Expansion into new indications and geographic markets presents growth opportunities.
FAQs
1. When will biosimilar competition likely impact Rucaparib prices?
Biosimilar entrants are expected around 2028–2030, based on patent expiration timelines and biosimilar development trends.
2. What are the main factors influencing future drug prices?
Market penetration, competition, biosimilar entry, reimbursement policies, and expanding indications.
3. How does Rucaparib compare price-wise to competitors?
Prices are comparable, with Lynparza and Zejula having similar list prices. However, market share influences actual pricing and discounts.
4. Are there regional pricing differences?
Yes, prices are generally lower outside the US due to regional pricing regulations and reimbursement policies.
5. What potential therapeutic advancements could impact the market?
Development of combination therapies, new PARP inhibitors, and better diagnostic tools for BRCA mutations.
References
- IQVIA. (2023). Oncology Market Trends Report.
- FDA. (2018). Labeling for Rubraca (rucaparib).
- IMS Health. (2022). Oncology drug pricing analysis.
- U.S. Patent and Trademark Office. (2021). Patent expiration data for Rubraca.
- GlobalData. (2022). PARP inhibitor market forecast.
